Latest Breaking News On - Arch biopartners inc - Page 3 : comparemela.com

Grant of Options to Directors and Officers

TORONTO, Dec. 18, 2023 Arch Biopartners Inc., , announced today that its Board of Directors has granted a total of 350,000 stock options to directors and officers pursuant to the Company s.

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Dec. 13, 2023 Arch Biopartners Inc., , announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT.

Arch Biopartners Submits Application to Health Canada to

Shares for Interest Debt Settlement

24.10.2023 - TORONTO, Oct. 24, 2023 (GLOBE NEWSWIRE) - Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $172,500 in . Seite 1

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Sept. 22, 2023 Arch Biopartners Inc., , announced that it has submitted applications to the Ministry of Health and local Ethics Committee in Turkey to obtain permission to proceed.